Advertisement

Drugs

, Volume 75, Issue 3, pp 243–251 | Cite as

Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges

  • Douglas S. Krakower
  • Kenneth H. Mayer
Current Opinion

Abstract

As the global incidence of HIV exceeds 2 million new infections annually, effective interventions to decrease HIV transmission are needed. Randomized, placebo-controlled studies have demonstrated that daily oral antiretroviral pre-exposure prophylaxis (PrEP) with a fixed-dose combination tablet containing tenofovir disoproxil fumarate and emtricitabine can significantly reduce HIV incidence among diverse at-risk populations. In these studies, the efficacy of PrEP was correlated with levels of adherence. Official guidelines recommend provision of PrEP to people at greatest risk of HIV acquisition, and demonstration projects suggest that high levels of uptake and adherence are possible outside of controlled studies. However, several potential barriers to implementing PrEP remain. These challenges include low awareness and utilization of PrEP by at-risk individuals, uncertainty about adherence in ‘real-world’ settings, the majority of healthcare providers being untrained in PrEP provision, limited data about potential adverse effects from long-term use of tenofovir–emtricitabine, high costs of PrEP medications, and stigma associated with PrEP use and the behaviors that would warrant PrEP. Innovative pharmacologic chemoprophylactic approaches could provide solutions to some of these challenges. Less-than-daily oral dosing regimens and long-acting injectable medications could reduce pill burdens and facilitate adherence, and local delivery of PrEP medications to genital compartments via gels, rings and films may limit systemic drug exposure and potential toxicities. As the portfolio of chemoprophylactic agents and delivery systems expands to meet the diverse sexual health needs and product preferences of individuals who may benefit from PrEP, it is hoped that antiretroviral chemoprophylaxis could become an acceptable, feasible, and highly effective addition to existing HIV prevention strategies.

Keywords

Tenofovir Tenofovir Disoproxil Fumarate Maraviroc Rilpivirine PrEP Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Funding: Douglas S. Krakower receives funding from the National Institutes of Health (K23 MH098795), and Kenneth H. Mayer receives funding from the Harvard University Center for AIDS Research (CFAR), a National Institutes of Health-funded program (P30 AI060354; PI: Walker).

Potential competing interests

Drs. Krakower and Mayer have conducted research with unrestricted Grants from Gilead Sciences (DSK and KHM), Bristol Myers Squibb (DSK and KHM), ViiV (KHM) and Merck (KHM). Drs. Krakower and Mayer have co-authored a continuing medical education (CME) activity for Medscape.

References

  1. 1.
    Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed 2 Nov 2014.
  3. 3.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMedGoogle Scholar
  8. 8.
    US FDA. FDA approves first medication to reduce HIV risk. 16 July 2012. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm311821.htm. Accessed 29 Oct 2014.
  9. 9.
    US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States: 2014 clinical practice guideline. Available at: http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed 5 Oct 2014.
  10. 10.
    Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Mayer KH, Oldenburg CE, Novak DS, Krakower DS, Mimiaga MJ. Differences in PrEP knowledge and use in US. MSM users of a popular sexual networking site surveyed in August 2013 and January 2014. R4P Conference; 28–31 Oct 2014; Cape Town.Google Scholar
  12. 12.
  13. 13.
    Marrazzo JM, Ramjee G, Nair GB, Palanee T, Mkhiza B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2013; Atlanta. Available at: http://www.retroconference.org/2013b/Abstracts/47951.htm. Accessed 12 Apr 2013.
  14. 14.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among Hiv-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 5 Oct 2014.
  22. 22.
    Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.CrossRefPubMedGoogle Scholar
  23. 23.
    Monteiro N, Branco M, Peres S, Borges F, Mansinho K. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. J Int AIDS Soc. 2014;17(4 Suppl 3):19565.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149–67.CrossRefPubMedGoogle Scholar
  25. 25.
    Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21(14):1899–907.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, et al. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. J Antimicrob Chemother. 2015;70(2):573–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, et al. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS. 2013;27(4):553–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra4.CrossRefPubMedGoogle Scholar
  29. 29.
    Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014;210(3):363–73.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903–10.CrossRefPubMedGoogle Scholar
  32. 32.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir–lamivudine or tenofovir disoproxil fumarate–emtricitabine along with efavirenz or atazanavir–ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–801.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–30.CrossRefPubMedGoogle Scholar
  34. 34.
    Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ, et al. Renal function of participants in the Bangkok tenofovir study: Thailand, 2005–2012. Clin Infect Dis. 2014;59(5):716–24.CrossRefPubMedGoogle Scholar
  35. 35.
    Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir–emtricitabine or placebo in Botswana. PLoS One. 2014;9(3):e90111.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Elion R, Doblecki-Lewis S, Cohen S, Castro J, Buchbinder S, Estrada Y, et al. High levels of interest in PrEP and baseline risk behaviors among MSM enrolled in the US PrEP Demonstration (Demo) project [abstract THPE187]. Presented at the 20th International AIDS Conference; 20–25 Jul 2014; Melbourne.Google Scholar
  39. 39.
    Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, et al. Implementation of PrEP in STD clinics: high uptake and drug detection among MSM in the Demonstration Project [abstract 954]. Presented at the 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.Google Scholar
  40. 40.
    Krakower D, Oldenburg CE, Mitty JA, Wilson I, Kurth A, Maloney K, et al. New England healthcare providers’ perceptions, knowledge and practices regarding the use of antiretrovirals for prevention. 9th International Conference on HIV Treatment and Prevention Adherence [abstract no. 270]; 8–10 Jun 2014; Miami.Google Scholar
  41. 41.
    Rawlings K, Mera R, Pechonika A, Rooney JF, Peschel T, Cheng A. Status of Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) in the United States: an early drug utilization analysis [abstract no. H-663a]. Presented at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy. 9–13 Sep 2013; Denver.Google Scholar
  42. 42.
    Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–8.Google Scholar
  43. 43.
    Mayer KH, Oldenburg CE, Novak D, Elsesser S, Krakower DS, Mimiaga MJ. Early adopters: socio-demographic and behavioral correlates of chemoprophylaxis use in a recent national online sample of men who have sex with men in the US [abstract no. 954].Presented at the 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.Google Scholar
  44. 44.
    Stott DB. The training needs of general practitioners in the exploration of sexual health matters and providing sexual healthcare to lesbian, gay and bisexual patients. Med Teach. 2013;35(9):752–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Sherman MD, Kauth MR, Shipherd JC, Street RL Jr. Communication between VA providers and sexual and gender minority veterans: a pilot study. Psychol Serv. 2014;11(2):235–42.CrossRefPubMedGoogle Scholar
  46. 46.
    Sherman MD, Kauth MR, Shipherd JC, Street RL. Provider beliefs and practices about assessing sexual orientation in two veterans health affairs hospitals. LGBT Health. 2014;1(3):185–91.Google Scholar
  47. 47.
    Gilead Sciences. Paying for Truvada. Available at: http://www.truvada.com/truvada-patient-assistance. Accessed 16 Oct 2014.
  48. 48.
    New York State Medicaid Pharmacy and Therapeutics Committee Meeting Summary, 15 Nov 2012. Available at: http://www.health.ny.gov/health_care/medicaid/program/ptcommittee/meetings/2012/11/ptsummary11-15-12_with_comm_final_determi.pdf. Accessed 5 Oct 2014.
  49. 49.
    Washinton State Department of Public Health. Pre-Exposure Prophyalxis Drug Assistance Program (PrEP DAP). Available at: http://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/HIVAIDS/HIVCareClientServices/PrEPDAP. Accessed 5 Oct 2014.
  50. 50.
    van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 Suppl 2):19146.PubMedCentralPubMedGoogle Scholar
  51. 51.
    AIDS Healthcare Foundation. An open letter to the CDC: What if you’re wrong about PrEP? Available at: http://www.aidshealth.org/wp-content/uploads/2014/11/PrEP-CDC-Open-Letter-What-if-Youre-Wrong-on-PrEP-ad-11-2014-DT1.pdf. Accessed 22 Nov 2014.
  52. 52.
    The New York Times. AIDS group wages lonely fight against pill to prevent H.I.V. 16 Nov 2014. Available at: http://www.nytimes.com/2014/11/17/upshot/aids-group-wages-lonely-fight-against-pill-to-prevent-hiv.html?_r=0&abt=0002&abg=1. Accessed 22 Nov 2014.
  53. 53.
    A significant breakthrough in the fight against HIV/AIDS: a drug taken at the time of sexual intercourse effectively reduces the risk of infection [press release]. The ANRS IPERGAY trial. 29 Oct 2014. Available at: http://www.avac.org/sites/default/files/u44/ipergayPR.pdf. Accessed 30 Oct 2014.
  54. 54.
    HPTN 067: The ADAPT Study: a phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). HIV Prevention Trials Network. Available at: http://www.hptn.org/research_studies/hptn067.asp. Accessed 30 Oct 2014.
  55. 55.
    Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(5):546–53.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    HPTN 069: NEXT-PREP: a phase II randomized, double-blind, study of the safety and tolerability of maraviroc (MVC), maraviroc + emtricitabine (MVC + FTC), maraviroc + tenofovir disoproxil fumarate (MVC + TDF), or tenofovir disoproxil fumarate + Eetricitabine (TDF + FTC) for pre-exposure prophylaxis (PrEP) to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. HIV Prevention Trials Network. Available at: http://www.hptn.org/research_studies/hptn069.asp. Accessed 16 Oct 2014.
  57. 57.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women [press release]. Microbicides Trial Network. 28 Nov 2011. Available at: http://www.mtnstopshiv.org/node/3909. Accessed 1 June 2012.
  59. 59.
    Follow-on African Consortium for Tenofovir Studies (FACTS). Available at: http://www.facts-consortium.co.za/?page_id=83. Accessed 31 Oct 2014.
  60. 60.
    McGowan I. The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv. 2014;11(1):69–82.CrossRefPubMedGoogle Scholar
  61. 61.
    Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.CrossRefPubMedGoogle Scholar
  62. 62.
    Chen B, Panther L, Hoesley C, Hendrix C, Van der Straten A, Husnik M, et al. Safety and pharmacokinetics/pharmacodynamics of dapivirine and maraviroc vaginal rings [abstract no. 41]. Presented at the 2014 Conference on Retroviruses and Oppportunistic Infections; 3–6 Mar 2014; Boston.Google Scholar
  63. 63.
    AIDS Vaccine Advocacy Coalition. Vaginal rings: products in development for HIV prevention and multipurpose technologies. Available at: http://www.avac.org/sites/default/files/resource-files/Vaginal%20Rings-Products%20in%20development.pdf. Accessed 21 Nov 2014.
  64. 64.
    Bunge KE, Dezzutti CS, Macio I, Hendrix C, Rohan LC, Marzinke MA, et al. FAME-02: a phase I trial to assess safety, PK and PD of gel and film formulations of dapivirine [abstract no. 42LB]. Presented at the 2014 Conference on Retroviruses and Oppportunistic Infections; 3–6 Mar 2014; Boston.Google Scholar
  65. 65.
    Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314–23.CrossRefPubMedGoogle Scholar
  66. 66.
    Penrose KJ, Parikh UM, Hamanishi KA, Panousis C, Else L, Back D, et al. Selection of rilpivirine-resistant HIV-1 in a seroconverter on long-acting rilpivirine (TMC278LA) from the lowest dose arm of the SSAT 040 Trial. AIDS Res Hum Retroviruses. 2014;30(S1):A69.CrossRefGoogle Scholar
  67. 67.
    Snyder O, Vincent H, Lachau-Durant S, Kraus G, Williams P, Garcia JV. Preclinical evaluation of TMC-278 LA, a long-acting formulation of rilpivirine, demonstrates significant protection from vaginal HIV Infection. AIDS Res Hum Retroviruses. 2014;30(Suppl 1):A11–2.CrossRefGoogle Scholar
  68. 68.
    McGowan I, Siegel A, Duffill K, Shetler C, Dezzutti C, Richardson-Harman N, et al. A phase 1 open label safety, acceptability, pharmacokinetic, and pharmacodynamic study of intramuscular TMC278 LA (the MWRI-01 Study). AIDS Res Hum Retroviruses. 2014;30(Suppl 1):A71.CrossRefGoogle Scholar
  69. 69.
    Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Spreen B, Rinehart A, Smith K, Margolis D, Ford S, Piscitelli S. HIV PrEP dose rationale for cabotegravir (GSK1265744) long-acting injectable nanosuspension. AIDS Res Hum Retroviruses. 2014;30(Suppl 1):A12.CrossRefGoogle Scholar
  71. 71.
    Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472–7.CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: products in development. Antiviral Res. 2013;100(Suppl):S39–47.CrossRefPubMedGoogle Scholar
  73. 73.
    CONRAD launches first-ever multipurpose vaginal ring clinical trial. 16 Nov 2014. Available at: http://www.conrad.org/news-pressreleases-105.html. Accessed 21 Nov 2014.
  74. 74.
    UNAIDS. 2011-2015 strategy: getting to zero. December 2010. Available at: http://www.unaids.org.ua/files/JC2034_UNAIDS_Strategy_en.pdf. Accessed 22 Nov 2014.
  75. 75.
    AIDS Vaccine Advocacy Coalition. HIV prevention research and development database. Available at: http://www.avac.org/pxrd. Accessed 2 Dec 2014.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Infectious DiseasesBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA
  2. 2.The Fenway InstituteFenway HealthBostonUSA

Personalised recommendations